ABSTRACT
Impact of timing of repair on outcomes of patients repaired with Hepp-Couinaud hepatico-jejunostomy (HC-HJ) after bile duct injury (BDI) during cholecystectomy remains debated. This is an observational retrospective study at a tertiary referral hepato-biliary center. HC-HJ was always performed in patients without sepsis or bile leak and with dilated bile ducts. Timing of repair was classified as: early (≤ 2 weeks), intermediate (> 2 weeks, ≤ 6 weeks), and delayed (> 6 weeks). 114 patients underwent HC-HJ between 1994 and 2022: 42.1% underwent previous attempts of repair at referring institutions (Group A) and 57.9% were referred without any attempt of repair before referral (Group B). Overall, a delayed HC-HJ was performed in 78% of patients; intermediate and early repair were performed in 17% and 6%, respectively. In Group B, 10.6% of patients underwent an early, 27.3% an intermediate, and 62.1% a delayed repair. Postoperative mortality was nil. Median follow-up was 106.7 months. Overall primary patency (PP) attainment rate was 94.7%, with a 5- and 10-year actuarial primary patency (APP) of 84.6% and 84%, respectively. Post-repair bile leak was associated with PP loss in the entire population (odds ratio [OR] 9.75, 95% confidence interval [CI] 1.64-57.87, p = 0.012); no correlation of PP loss with timing of repair was noted. Treatment of anastomotic stricture (occurred in 15.3% of patients) was performed with percutaneous treatment, achieving absence of biliary symptoms in 93% and 91% of cases at 5 and 10 years, respectively. BDI can be successfully repaired by HC-HJ regardless of timing when surgery is performed in stable patients with dilated bile ducts and without bile leak.
Subject(s)
Bile Ducts , Cholecystectomy, Laparoscopic , Humans , Bile Ducts/surgery , Bile Ducts/injuries , Jejunostomy , Retrospective Studies , Tertiary Care Centers , Cholecystectomy/adverse effects , Cholecystectomy, Laparoscopic/adverse effects , Treatment OutcomeABSTRACT
BACKGROUND AND OBJECTIVE: A mathematical procedure was developed to obtain an accurate coefficient (-∆BEB) for the correction of blood base excess to full hemoglobin-O2 saturation taking into account actual 2,3-diphosphoglycerate (2,3-DPG) concentration. METHODS: Previously published laboratory data were carefully processed through regression analysis, by correlating laboratory measurements of -∆BEB with the corresponding values of plasma pH, CO2 tension and 2,3-DPG. RESULTS: Data processing allowed the development of two accurate fits to the original laboratory results for blood with normal 2,3-DPG and for blood depleted of 2,3-DPG (r2 = 0.990 and 0.986, respectively, p < 0.0001 for both), as the main components of a procedure for estimating the correction factor in normal conditions and in moderate-to-extreme illness with extreme acid-base abnormalities. CONCLUSIONS: This regression-derived procedure can easily integrate any computer system to automatically obtain an accurate correction factor on the basis of plasma pH, CO2 tension, and 2,3-DPG concentration if available. It may also allow for the assessment of small stoichiometric quantities involved in O2-linked H+ exchange and equilibrium (Haldane effect) in computer programs dedicated to these types of investigations.
Subject(s)
Carbon Dioxide , Oxygen , Hemoglobins , Hydrogen-Ion Concentration , OximetryABSTRACT
[This corrects the article DOI: 10.1155/2020/2291759.].
ABSTRACT
The ratio of venoarterial CO2 tension to arteriovenous O2 content difference (P[v-a]CO2/C[a-v]O2) increases when lactic acidosis is due to inadequate oxygen supply (hypoxia); we aimed to verify whether it also increases when lactic acidosis develops because of mitochondrial dysfunction (dysoxia) with constant oxygen delivery. Twelve anaesthetised, mechanically ventilated pigs were intoxicated with IV metformin (4.0 to 6.4 g over 2.5 to 4.0 h). Saline and norepinephrine were used to preserve oxygen delivery. Lactate and P[v-a]CO2/C[a-v]O2 were measured every one or two hours (arterial and mixed venous blood). During metformin intoxication, lactate increased from 0.8 (0.6-0.9) to 8.5 (5.0-10.9) mmol/l (p < 0.001), even if oxygen delivery remained constant (from 352 ± 78 to 343 ± 97 ml/min, p = 0.098). P[v-a]CO2/C[a-v]O2 increased from 1.6 (1.2-1.8) to 2.3 (1.9-3.2) mmHg/ml/dl (p = 0.004). The intraclass correlation coefficient between lactate and P[v-a]CO2/C[a-v]O2 was 0.72 (p < 0.001). We conclude that P[v-a]CO2/C[a-v]O2 increases when lactic acidosis is due to dysoxia. Therefore, a high P[v-a]CO2/C[a-v]O2 may not discriminate hypoxia from dysoxia as the cause of lactic acidosis.
Subject(s)
Acidosis, Lactic/blood , Acidosis, Lactic/chemically induced , Carbon Dioxide/blood , Hypoglycemic Agents/adverse effects , Metformin/adverse effects , Mitochondrial Diseases/blood , Mitochondrial Diseases/chemically induced , Oxygen/blood , Acidosis, Lactic/diagnosis , Animals , Cell Hypoxia/physiology , Disease Models, Animal , Hypoglycemic Agents/administration & dosage , Lactic Acid/blood , Metformin/administration & dosage , Mitochondrial Diseases/diagnosis , SwineABSTRACT
INTRODUCTION: Serum amino acid (AA) profiles represent a valuable tool in the metabolic assessment of cancer patients; still, information on the AA pattern in head and neck cancer (HNC) patients is insufficient. The aim of the study was to assess whether serum AA levels were associated with the stage of neoplastic disease and prognosis in primary HNC patients. METHODS: Two hundred and two primary HNC patients were included in the study. Thirty-one AAs and derivatives were measured in serum through an ultraperformance liquid chromatography-mass spectrometry (UPLC-MS). The association between AA concentrations and the stage (advanced versus early) of HNC was estimated using a multivariable logistic regression model. A multivariable Cox regression model was used to evaluate the prognostic significance of each AA. RESULTS: At the multivariable logistic regression analysis, increased levels of alpha-aminobutyric acid, aminoadipic acid, histidine, proline, and tryptophan were associated with a reduced risk of advanced stage HNC, while high levels of beta-alanine, beta-aminobutyric acid, ethanolamine, glycine, isoleucine, 4-hydroxyproline, and phenylalanine were associated with an increased risk of advanced stage HNC. Furthermore, at multivariate analysis, increased levels of alpha-aminobutyric acid were associated with increased overall survival (OS), while high levels of arginine, ethanolamine, glycine, histidine, isoleucine, 4-hydroxyproline, leucine, lysine, 3-methylhistidine, phenylalanine, and serine were associated with decreased OS. CONCLUSIONS: Our study suggests that AA levels are associated with the stage of disease and prognosis in patients with HNC. More study is necessary to evaluate if serum AA levels may be considered a hallmark of HNC and prove to be clinically useful markers of disease status and prognosis in HNC patients.
Subject(s)
Amino Acids/blood , Biomarkers, Tumor/blood , Head and Neck Neoplasms/pathology , Chromatography, Liquid , Combined Modality Therapy , Female , Follow-Up Studies , Head and Neck Neoplasms/blood , Head and Neck Neoplasms/therapy , Humans , Male , Middle Aged , Prognosis , Survival Rate , Tandem Mass SpectrometryABSTRACT
BACKGROUND: It is still unclear whether a positive surgical margin after resection of colorectal liver metastases remains a poor prognostic factor in the era of modern perioperative chemotherapy. The aim of this study was to evaluate whether preoperative chemotherapy has an impact on reducing local recurrence after R1 resection, and the impact of local recurrence on overall survival. METHODS: Between 2000 and 2014, a total of 421 patients underwent resection for colorectal liver metastases at our unit after preoperative chemotherapy. The overall number of analyzed resection areas was 1,428. RESULTS: The local recurrence rate was 12.8%, significantly higher after R1 resection than after R0 (24.5% vs 8.7%; P < .001). These results were also confirmed in patients with response to preoperative chemotherapy (23.1% after R1 vs 11.2% after R0; P < .001). At multivariate analysis, R1 resection was the only independent risk factor for local recurrence (P < .001). At the analysis of the 1,428 resection areas, local recurrence significantly decreased according to the increase of the surgical margin width (from 19.1% in 0 mm margin to 2.4% in ≥10 mm). At multivariable logistic regression analysis for overall survival, the presence of local recurrence showed a significant negative impact on 5-year overall survival (P < .001). CONCLUSION: Surgical margin recurrence after modern preoperative chemotherapy for colorectal liver metastases was still significantly higher after R1 resection than it was after R0 resection. Local recurrence showed a negative prognostic impact on overall survival. R0 resection should be recommended whenever technically achievable, as well as in patients treated by modern preoperative chemotherapy.
Subject(s)
Hepatectomy/methods , Liver Neoplasms/secondary , Liver Neoplasms/surgery , Neoplasm Recurrence, Local/epidemiology , Adult , Aged , Aged, 80 and over , Colorectal Neoplasms/pathology , Humans , Liver Neoplasms/mortality , Middle AgedSubject(s)
Sepsis , Shock, Septic , Child , Humans , Intensive Care Units, Pediatric , Lipid MetabolismABSTRACT
Plasma chitotriosidase activity (ChT) was previously proposed to quantify severity of sepsis. In a complex surgical case, with prolonged sepsis and consistently high ChT, we found that the least increased values occurred in stages of extreme illness, with profound hypocholesterolemia. ChT needs better characterization before becoming a reliable biomarker of septic evolution.
Subject(s)
Hexosaminidases/blood , Sepsis/blood , Aged , Biomarkers/blood , Humans , MaleABSTRACT
INTRODUCTION: The Y-box binding protein-1 (YB-1) is a multifunctional oncoprotein involved in the proliferation and aggressiveness of cancer cells. The aim of this study was to determine whether strong YB-1 expression in neoplastic cells of colorectal liver metastases (CRLM) may have an impact on liver disease-free survival following liver resection. MATERIALS AND METHODS: Immunohistochemistry was performed to evaluate YB-1 in 66 patients who underwent liver resection for CRLM. YB-1 expression was classified as weak (low-staining intensity) and strong (high-staining intensity). RESULTS: YB-1 expression was observed in the cytoplasm of all CRLM. YB-1 expression was weak in 17 patients (25.8%) and strong in 49 patients (74.2%). Liver recurrence rate was significantly higher in the strong than in the weak expression group: 55.1 vs. 23.5% (p = 0.023). Multivariable logistic regression analysis showed that YB-1 strong expression was the only independent risk factor for liver recurrence. The 5-year specific liver disease-free survival rate was 76.0% in the weak expression group and 41.5% in the strong expression group (p = 0.034). These results were not influenced by clinical prognostic factors of tumor recurrence. CONCLUSIONS: This is the first study showing that the degree of YB-1 expression in tissue specimens of CRLM predicts liver recurrence following liver resection.
Subject(s)
Biomarkers, Tumor/analysis , Colorectal Neoplasms/pathology , Liver Neoplasms/secondary , Liver Neoplasms/surgery , Neoplasm Recurrence, Local/pathology , Y-Box-Binding Protein 1/metabolism , Adult , Aged , Aged, 80 and over , Cohort Studies , Colorectal Neoplasms/mortality , Colorectal Neoplasms/surgery , Disease-Free Survival , Female , Hepatectomy/methods , Hepatectomy/mortality , Humans , Immunohistochemistry , Kaplan-Meier Estimate , Liver Neoplasms/mortality , Logistic Models , Male , Middle Aged , Multivariate Analysis , Neoplasm Recurrence, Local/mortality , Predictive Value of Tests , Prognosis , Retrospective Studies , Survival Analysis , Treatment Outcome , Y-Box-Binding Protein 1/geneticsABSTRACT
The determination of plasma phosphoserine concentration in sepsis is uncommon, and the clinical and metabolic correlations of abnormally high phosphoserine are basically unknown. We analyzed 430 determinations of phosphoserine, other amino acid (AA) levels and ancillary variables obtained in 18 septic patients, in order to assess the biochemical and clinical correlations of changes in phosphoserine. Phosphoserine ranged between 5 and 55 micromol/L (n.v. < 12). Increasing phosphoserine was associated with higher severity of illness and death, and its best AA correlates were increasing cystathionine, 3-methylhistidine, histidine, hydroxyproline and tyrosine (r > 0.65, p < 0.001 for all). High phosphoserine seemed to cumulatively reflect kidney and liver dysfunction and enhanced proteolysis. As a collateral finding, 3-methylhistidine (a best correlate of phosphoserine) was also inversely related to nutritional AA dose (p < 0.001). These data suggest that in septic patients the determination of plasma phosphoserine may provide useful information on severity of septic illness and prognosis. The observed correlations also indirectly evidenced an impact of nutritional AA dose in moderating proteolysis.
ABSTRACT
BACKGROUND: We aimed to evaluate the feasibility and long-term results of 2-stage hepatectomy (TSH) in patients with bilobar colorectal liver metastases (CRLM). STUDY DESIGN: We performed a retrospective multicenter study including 4 Italian hepatobiliary surgery units. One hundred thirty patients were selected for TSH between 2002 and 2011. The primary endpoint was feasibility of TSH and analysis of factors associated with failure to complete the procedure. The secondary endpoint was the long-term survival analysis. RESULTS: Patients presented with synchronous CRLM in 80.8% of cases, with a mean number of 8.3 CRLM and with concomitant extrahepatic disease in 20.0% of cases. The rate of failure to complete TSH was 21.5% and tumor progression was the most frequent reason for failure (18.5% of cases). Primary tumor characteristics, type, number, and distribution of CRLM were not associated with significantly different risks of disease progression. Multivariable logistic regression analysis showed that tumor progression during prehepatectomy chemotherapy was the only independent risk factor for failure to complete TSH. The 5- and 10-year overall survival rates for patients who completed TSH were 32.1% and 24.1%, respectively, with a median survival of 43 months. Duration of prehepatectomy chemotherapy ≥6 cycles was found to be the only independent predictor of overall and disease-free survival. CONCLUSIONS: This study showed that selection of patients by response to prehepatectomy chemotherapy may be extremely important before planning TSH because tumor progression while receiving prehepatectomy chemotherapy was associated with significantly higher risk of failure to complete the second stage. For patients who completed the TSH strategy, long-term outcomes can be achieved with results similar to those observed after single-stage hepatectomy.
Subject(s)
Antineoplastic Agents/administration & dosage , Colorectal Neoplasms/pathology , Hepatectomy/methods , Liver Neoplasms/drug therapy , Liver Neoplasms/secondary , Liver Neoplasms/surgery , Adult , Aged , Aged, 80 and over , Combined Modality Therapy , Disease Progression , Embolization, Therapeutic , Feasibility Studies , Female , Humans , Italy , Male , Middle Aged , Retrospective Studies , Risk Factors , Survival Rate , Treatment FailureABSTRACT
BACKGROUND: Simple liver cysts (LCs) represent the most common benign liver disease, with a prevalence of 3-5%. Laparoscopic fenestration is considered the best treatment for symptomatic LCs, but few studies have analyzed the rate or type of recurrence during a long-term follow-up period (>5 years). METHODS: Between January 2000 and December 2010, 47 patients underwent laparoscopic fenestration for simple LCs. The indications were symptoms for 42 patients and an uncertain diagnosis for five patients. The follow-up assessment consisted of regular patient evaluations, with results of laboratory data and liver ultrasound. RESULTS: Conversion to laparotomy was not necessary in any case. The postoperative mortality and morbidity rates were nil. The mean follow-up period was 67 months (range 12-142 months), and 26 patients (55.3%) had a follow-up period longer than 5 years. During the follow-up period, 40 patients (85.1%) did not present with any type of recurrence. The overall recurrence rate was 14.9% (seven patients) based on five patients (10.6%) with radiologic asymptomatic recurrences detected by ultrasound or computed tomography (CT) scan and two patients (4.3%) with clinicoradiologic symptomatic recurrences. Both symptomatic recurrences involved LCs located in the right posterior segments. CONCLUSIONS: Laparoscopic fenestration provided complete relief of symptoms for about 95% of patients with simple LCs. Recurrence after surgery was experienced by 14.9% of the patients, but only in 4.3% (two patients) was this recurrence symptomatic requiring a second treatment. The site of recurrence was more frequently in the right posterior segments. Laparoscopic fenestration of symptomatic LCs can be considered a safe and effective procedure that can yield good long-term results.
Subject(s)
Cysts/surgery , Laparoscopy/methods , Liver Diseases/surgery , Adult , Aged , Female , Follow-Up Studies , Humans , Male , Middle Aged , Postoperative Period , Recurrence , Retrospective Studies , Time Factors , Young AdultABSTRACT
BACKGROUND: Portal vein embolization (PVE) is an effective procedure to increase the future remnant liver (FRL) before major hepatectomy. A controversial issue is that PVE may stimulate tumor growth and can be associated with poor prognosis after liver resection for colorectal liver metastases (CRLM). The aim of this study was to evaluate the impact of PVE on long-term survival following major hepatectomy for CRLM. METHODS: Between 1998 and 2010, 100 right and extended-right hepatectomies for unilobar, right-sided CRLM were performed. Of the group, 20 patients underwent preoperative PVE (group A). The control patients (group B; 20 patients) were selected by matching with the group A patients. RESULTS: It was found that 25 patients (25/40; 62.5%) had developed tumor recurrence. The rate of global recurrence was not significantly different in groups A and B (65% vs 60%, respectively; P = .744). The specific overall intrahepatic recurrence rate was 42.5% (17 of 40 patients) and was not significantly different in groups A and B (45% vs 40%, respectively; P = .749). The 5-year overall and disease-free survival rates were similar in groups A and B (42.9% and 33.6% vs 42.1% and 27.7%, respectively). The 5-year specific liver-disease-free survival was 45.3% in group A and 53.5% in group B (P = .572). On multivariate analysis of all 100 hepatectomies, R1 resection (P = .013) was found to be the only independent predictor of liver-disease-free survival. CONCLUSION: This study showed that PVE did not affect overall survival and specific liver-disease-free survival in patients undergoing right or right-extended hepatectomy for unilobar, right-sided CRLM.
Subject(s)
Colorectal Neoplasms , Embolization, Therapeutic , Hepatectomy/methods , Liver Neoplasms/secondary , Liver Neoplasms/surgery , Portal Vein , Adult , Aged , Aged, 80 and over , Case-Control Studies , Combined Modality Therapy , Disease-Free Survival , Embolization, Therapeutic/adverse effects , Female , Humans , Kaplan-Meier Estimate , Liver Neoplasms/prevention & control , Male , Middle Aged , Neoplasm Recurrence, Local , Prospective Studies , Treatment Outcome , Young AdultABSTRACT
OBJECTIVE: The aim of this study was to determine the prognostic significance of the preoperatively assessed tumor doubling time (DT) in patients undergoing liver resection for mass-forming intrahepatic cholangiocarcinoma (IHC). METHODS: We evaluated 79 patients who underwent curative resection for IHC, and in whom the same imaging technique was preoperatively available in two consecutive occasions, to allow the calculation of the DT. The influence of DT and other clinical and pathological variables on tumor recurrence and patient survival was determined by the Kaplan-Meier method and uni- and multivariate analysis. RESULTS: Median overall survival was 40 months; 1-, 3-, and 5-year survival rates were 86.1, 55.1, and 35.1 %, respectively. Median disease-free survival was 17 months; 1-, 3-, and 5-year disease-free survival rates were 62.0, 29.1, and 23.3 %, respectively. At univariate analysis, DT <70 days (p < 0.001) and advanced tumor stage (p = 0.024) were associated with worse overall survival and maintained significance at multivariate analysis. CONCLUSIONS: DT is a clinically useful parameter to estimate the prognosis of "mass-forming" IHC in patients undergoing liver resection.